65,437 trials
Gastroesophageal Reflux Disease
Primary: Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Heartburn — 3.10; 1.36 units on a scale
Erosive Gastroesophageal Reflux Disease · Non-Erosive Reflux Disease
Primary: Assessment of the Severity of Sleep Disturbances — 13.8; 77.4; 38.2; 20.0 percentage of participants
Acne
Primary: Maintenance Success for Total Lesions at Week 24 — 78.9; 45.8 percent of subjects
Chronic Nonmalignant Pain
Primary: Number of Participants With Adverse Events (AEs) as a Measure of Safety. — 1; 16; 143 participants
Urinary Tract Infection
Primary: Number of Urine Cultures Collected Out of the Total Number Expected to be Collected. — 81; 74; 85; 73 Urine cultures
Kidney Transplantation
Primary: Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR) — 47; 46 ml/min — p=<0.05
Heart Failure
Primary: Clinical Composite Score — 230; 235; 229; 84 participants — p=0.55
Liver Diseases
Primary: Change From Baseline in Platelet Counts on Day 15 — 24.8; 54.0; 60.0 10^9/Liter
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Asthma
Primary: Possible Drug-Related Adverse Events — 13; 16; 9; 4 participants
Ocular Inflammation
Primary: Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0 — 64; 23 participants
Ocular Inflammation
Primary: Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0. — 48; 27; 153; 172 participants
Osteoarthritis
Primary: The Percentage of Subjects Who Completed the 14-day Double-blind Phase. — 88; 83; 85; 85 Percentage of Participants
Nasal Polyps · Gastroesophageal Reflux
Primary: Presence of Reflux in Patients With Polyposis — 15 participants
Chalazion · Hordeolum
Primary: Treatment Emergent Adverse Events — 2; 0; 1; 1 participants